These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1187 related articles for article (PubMed ID: 29165391)
1. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review. Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391 [TBL] [Abstract][Full Text] [Related]
2. The emerging role of nuclear factor kappa B in renal cell carcinoma. Morais C; Gobe G; Johnson DW; Healy H Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869 [TBL] [Abstract][Full Text] [Related]
4. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma. Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867 [TBL] [Abstract][Full Text] [Related]
5. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178 [TBL] [Abstract][Full Text] [Related]
6. Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways. Lichner Z; Mejia-Guerrero S; Ignacak M; Krizova A; Bao TT; Girgis AH; Youssef YM; Yousef GM Am J Pathol; 2012 Apr; 180(4):1675-87. PubMed ID: 22326755 [TBL] [Abstract][Full Text] [Related]
7. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism. Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500 [TBL] [Abstract][Full Text] [Related]
8. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414 [TBL] [Abstract][Full Text] [Related]
9. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Rohan SM; Xiao Y; Liang Y; Dudas ME; Al-Ahmadie HA; Fine SW; Gopalan A; Reuter VE; Rosenblum MK; Russo P; Tickoo SK Mod Pathol; 2011 Sep; 24(9):1207-20. PubMed ID: 21602815 [TBL] [Abstract][Full Text] [Related]
10. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME. Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701 [TBL] [Abstract][Full Text] [Related]
11. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124 [TBL] [Abstract][Full Text] [Related]
12. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related]
13. Molecular biology of renal cell cancer and the identification of therapeutic targets. Iliopoulos O J Clin Oncol; 2006 Dec; 24(35):5593-600. PubMed ID: 17158545 [TBL] [Abstract][Full Text] [Related]
14. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma. Petrella BL; Brinckerhoff CE Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472 [TBL] [Abstract][Full Text] [Related]
15. From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer. Chung C Am J Health Syst Pharm; 2020 Dec; 77(24):2064-2073. PubMed ID: 33016992 [TBL] [Abstract][Full Text] [Related]
16. Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth. Chen L; Xia G; Qiu F; Wu C; Denmon AP; Zi X Sci Rep; 2016 Sep; 6():32582. PubMed ID: 27581364 [TBL] [Abstract][Full Text] [Related]
17. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929 [TBL] [Abstract][Full Text] [Related]
18. MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review). Li M; Wang Y; Song Y; Bu R; Yin B; Fei X; Guo Q; Wu B Oncol Rep; 2015 Apr; 33(4):1571-8. PubMed ID: 25682771 [TBL] [Abstract][Full Text] [Related]
19. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836 [TBL] [Abstract][Full Text] [Related]
20. VHL and HIF signalling in renal cell carcinogenesis. Baldewijns MM; van Vlodrop IJ; Vermeulen PB; Soetekouw PM; van Engeland M; de Bruïne AP J Pathol; 2010 Jun; 221(2):125-38. PubMed ID: 20225241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]